CAR- has raised $20m from a US public offering to expand its CAR -T and gene-editing capabilities. The French company is planning to invest $100m of the funding on expanding commercial production, including setting up a manufacturing plant for its CAR- -T candidates, $164m on starting clinical development on another programme and $30m to develop its gene-editing technology for non-oncological uses. Meanwhile, Cellectis ’s partnership with Pfizer for 17 readymade CAR- Ts has been converted into a new company, Allogene , which has taken over US rights to lead CAR-T UCART19 for acute lymphoblastic leukaemia, and is backed by $300m of funding.
Cellectis has raised $164m from a US public offering to expand its CAR-T and gene-editing capabilities. The French company is planning to invest $100m of the funding on expanding commercial production, including setting up a manufacturing plant for its CAR-T candidates, $20m on starting clinical development on another programme and $30m to develop its gene-editing technology for non-oncological uses. Meanwhile, Cellectis’s partnership with Pfizer for 17 readymade CAR-Ts has been converted into a new company, Allogene, which has taken over US rights to lead CAR-T UCART19 for acute lymphoblastic leukaemia, and is backed by $300m of funding.